Are anti-APOE Alzheimer’s therapies safe?

A New York Times piece reviews recent research on the safety of potential Alzheimer’s therapies that focus on genetic factors of the disease. APOE is a hallmark risk factor and perhaps the most common in those who progress to Alzheimer’s, and often earlier than others.

People with two copies of APOE4 have as much as 15 times the risk of developing Alzheimer’s compared to those with only one copy. Those with only one copy still have as much as five times the risk of developing Alzheimer’s. Researchers explore whether someone could live without this gene and what that would mean for the brain.
 

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.